# US 2024/0189315 A1 · Cyclic Pyridine Derivatives as cGAS Inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189315 A1
- Document ID: US20240189315A1
- Status: Published application
- Kind: A1
- Application number: 18/501,509
- Filed: 2023-11-03
- Published: 2024-06-13
- Earliest claimed: 2022-11-09
- Assignees: Boehringer Ingelheim International GmbH
- Applicants: Boehringer Ingelheim International GmbH
- Inventors: Annekatrin Charlotte HEIMANN; Christian GNAMM; Cédrickx GODBOUT; Sandra Ruth HANDSCHUH; Christoph HOENKE; Joerg Thomas KLEY; Christian Andreas KUTTRUFF; Jun LI; Dirk REINERT; Raphael STUBER; Theodor THEIS
- Web page: https://patentgrep.com/patent/US20240189315A1

## CPC

- A61K 31/529: forming part of bridged ring systems
- A61K 31/4418: having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/12: Antivirals
- A61P 37/00: Drugs for immunological or allergic disorders
- C07D 498/22: in which the condensed system contains four or more hetero rings
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The invention relates to compounds of formula I wherein R1, R2, R3, R4, A, D, E, G, J, K and L are defined as in claim 1, and prodrugs, deuterated analogues and pharmaceutical acceptable salts thereof, for the treatment of diseases such as systemic lupus erythematosus, systemic sclerosis (SSc), interferonopathies, non-alcoholic steatohepatitis (NASH), interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF).

## Claims

### Claim 1

A compound of formula I
wherein
R1 is selected from the group consisting of hydrogen, halogen, methyl, ethyl, —CF3, —CHF2, —CFH2 and methoxy,
R2 is selected from the group consisting of hydrogen and methyl;
R3 is selected from the group consisting of hydrogen, methyl, halogen, ethinyl, propinyl, —CO—(C1-3-alkyl), —CO—NH2, —CO—NHCH3, —CO—N(CH3)2 and a 5- or 6-membered heteroaryl ring with 1 or 2 heteroatoms each independently selected from N, S or O, whereby this heteroaryl ring may optionally be further substituted by one or two further substituents each independently selected from the group consisting of F, Cl, Br, —O—CH3, methyl, —CF3, —CHF2, CH2F;
R4 is selected from the group consisting of hydrogen, —OH and F;
and wherein
A is selected from the group consisting of —CH2—, —O—, —CF2— and —CHCH3—;
D is selected from the group consisting of —CH2—, —O—, —CF2— and —CHCH3—;
E is selected from the group consisting of —CH2—, —CO—, —O—, —CF2— and —CHCH3—;
G is selected from the group consisting of —NH—, —NCH3—, —CH2—, —O—, —CF2— and —CHCH3—;
J is selected from the group consisting of —CO—, —CH2—, —O—, —CF2— and —CHCH3—;
K is selected either from the group consisting of —CH2—, —CF2— and —O— or is absent;
L is selected either from the group consisting of —CH2—, —CHCH3— and —CF2— or is absent;
and prodrugs, deuterated analogues and pharmaceutical acceptable salts thereof.

### Claim 2 (depends on 1)

The compound of formula II according to claim 1, wherein
R1 is selected from the group consisting of hydrogen and or wherein the halogen is selected from the group consisting of F and Cl;
R2 is selected from the group consisting of hydrogen and methyl;
R3 is selected from the group consisting of hydrogen, Cl, Br, ethinyl, propinyl, —CO—(CH3) and a 5- or 6-membered heteroaryl ring with 1 or 2 heteroatoms each independently selected from N, S or O, whereby this heteroaryl ring may optionally be further substituted by one or two further substituents each independently selected from the group consisting of F, —O—CH3 and methyl;
R4 is F;
and wherein
A is selected from the group consisting of —CH2—, —O—, —CF2—, and —CHCH3—;
D is selected from the group consisting of —CH2— and —O—;
E is selected from the group consisting of —CH2—, —CO— and —O—;
G is selected from the group consisting of —NH—, —NCH3—, —CH2— and —O—;
J is selected from the group consisting of —CO—, —CH2— and —O—;
K is either selected from the group consisting of —CH2—, —CF2— and —O— or is absent;
L is either —CH2— or is absent;
and prodrugs, deuterated analogues and pharmaceutical acceptable salts thereof.

### Claim 3 (depends on 1)

The compound of formula I according to claim 1, wherein L is absent,
and prodrugs, deuterated analogues and pharmaceutical acceptable salts thereof.

### Claim 4 (depends on 1)

The compound of formula I according to claim 1, wherein L and K are absent,
and prodrugs, deuterated analogues and pharmaceutical acceptable salts thereof.

### Claim 5 (depends on 1)

The compound of formula I according to claim 1, wherein L is absent and wherein K is —CF2—,
and prodrugs, deuterated analogues and pharmaceutical acceptable salts thereof.

### Claim 6 (depends on 1)

The compound of formula I according to claim 1, wherein L is absent and wherein A is selected from the group consisting of —CH2— and —CF2—,
and prodrugs, deuterated analogues and pharmaceutical acceptable salts thereof.

### Claim 7 (depends on 1)

The compound of formula I according to claim 1, wherein L is absent and whereby A is —O—,
and prodrugs, deuterated analogues and pharmaceutical acceptable salts thereof.

### Claim 8 (depends on 1)

The compound of formula I according to claim 1, wherein L is absent and wherein D is —O—,
and prodrugs, deuterated analogues and pharmaceutical acceptable salts thereof.

### Claim 9 (depends on 1)

The compound of formula I according to claim 1, wherein L is absent and wherein R3 is selected from the group consisting of Cl, Br, ethinyl, propinyl and a 5- or 6-membered heteroaryl ring selected from the group consisting of pyridinyl and pyrazolyl, whereby this heteroaryl ring may optionally be further substituted by one or two further substituents each independently selected from the group consisting of F, —O—CH3 and methyl;
and prodrugs, deuterated analogues and pharmaceutical acceptable salts thereof.

### Claim 10 (depends on 1)

The compound of formula I according to claim 1, wherein R1 is selected from the group consisting of F and Cl,
and prodrugs, deuterated analogues and pharmaceutical acceptable salts thereof.

### Claim 11 (depends on 1)

The compound of formula I according to claim 1, wherein R1 is hydrogen,
and prodrugs, deuterated analogues and pharmaceutical acceptable salts thereof.

### Claim 12 (depends on 1)

The compound of formula I according to claim 1, which is selected from the group consisting of
and prodrugs, deuterated analogues and pharmaceutical acceptable salts thereof.

### Claim 13 (depends on 1)

The compound of formula I according to claim 1, wherein
A is selected from the group consisting of —CH2— and —O—;
D is selected from the group consisting of —CH— and —O—;
E is selected from the group consisting of-CH2— and —O—;
G is selected from the group consisting of —CH— and —O—;
J is selected from the group consisting of —CH2— and —O—;
K is either selected from the group consisting of —CH2— and —CF2—;
L is absent;
and prodrugs, deuterated analogues and pharmaceutical acceptable salts thereof.

### Claim 14 (depends on 1)

The compound of formula I according to claim 1, which is selected from the group consisting of
and prodrugs, deuterated analogues and pharmaceutical acceptable salts thereof.

### Claim 15 (depends on 1)

The compound of formula I according to claim 1, wherein
A is selected from the group consisting of —CH2-and —O—;
D is selected from the group consisting of —CH2-and —O—;
E is —CH2—;
G is selected from the group consisting of —CH2-and —O—;
J is —CH2—;
K is either selected from the group consisting of —CH2— and —CF2—;
L is absent;
and prodrugs, deuterated analogues and pharmaceutical acceptable salts thereof.

### Claim 16 (depends on 1)

The compound of formula I according to claim 1, which is selected from the group consisting of
and prodrugs, deuterated analogues and pharmaceutical acceptable salts thereof.

### Claim 17 (depends on 1)

An intermediate compound of
a) formula (A-I)
wherein R1, R2, R3, R4, A, D, E, G, J, K and L are defined as in claim 1 and wherein R13 is selected from the group consisting of hydrogen, methyl, ethyl and tert-butyl,
b) formula A-II
wherein R1, R2, R3, R4, A, D, E, G, J, K and L are defined as in claim 1, wherein R13 is selected from the group consisting of hydrogen, methyl, ethyl and tert-butyl, and wherein R is either hydrogen or a protecting group selected from the group consisting of tert-butyl, methyl, ethyl and benzyl,
c) formula (B-I)
wherein R1, R2, R3, R4, A, D, E, G, J, K and L are defined as in claim 1 and wherein R13 is selected from the group consisting of hydrogen, methyl, ethyl and tert-butyl,
d) formula (C-I)
wherein R1, R2, R3, R4, A, D, E, G, J, K and L are defined as in claim 1 and wherein R13 is selected from the group consisting of hydrogen, methyl, ethyl and tert-butyl,
or of
e) formula (C-II)
wherein R1, R2, R3, R4, A, D, E, G, J, K and L are defined as in claim 1 and wherein R13 is selected from the group consisting of hydrogen, methyl, ethyl and tert-butyl,
wherein PG is selected from the group consisting of tert-butoxycarbonyl (Boc), allyloxycarbonyl (Alloc), benzyloxycarbonyl (Cbz) and fluorenylmethoxycarbonyl (Fmoc).

### Claim 18 (depends on 1)

A method of treating in a patient a disease that can be treated by the inhibition of cGAS, said method comprising administering to the patient a compound of formula I according to claim 1.

### Claim 19 (depends on 1)

A method of treating a disease in a patient, said method comprising administering to the patient a compound of formula I according to claim 1, wherein the disease is selected from the group consisting of systemic lupus erythematosus (SLE), interferonopathies, Aicardi-Goutières syndrome (AGS), COPA syndrome, familial chilblain lupus, age-related macular degeneration (AMD), amyotrophic lateral sclerosis (ALS), retinopathy, glaucoma, diabetes, obesity, inflammatory bowel disease (IBD), chronic obstructive pulmonary disease (COPD), Bloom's syndrome, dermatomyositis, Sjogren's syndrome, Parkinsons disease, heart failure, cancer, aging, muscle disorders, sepsis, rheumatoid arthritis, osteoarthritis, COVID-19, systemic sclerosis (SSc), non-alcoholic steatotic hepatitis (NASH), interstitial lung disease (ILD), progressive fibrosing interstitial lung disease (PF-ILD), and idiopathic pulmonary fibrosis (IPF).

### Claim 20 (depends on 19)

The method according to claim 19, wherein the disease is selected from the group consisting of systemic lupus erythematosus (SLE), interferonopathies, Aicardi-Goutières syndrome (AGS), COPA syndrome, familial chilblain lupus, dermatomyositis, age-related macular degeneration (AMD), amyotrophic lateral sclerosis (ALS), inflammatory bowel disease (IBD), chronic obstructive pulmonary disease (COPD), Bloom's syndrome, Sjogren's syndrome, rheumatoid arthritis and Parkinsons disease.

### Claim 21 (depends on 19)

The method according to claim 19, wherein the disease is selected from the group consisting of systemic sclerosis (SSc), non-alcoholic steatohepatitis (NASH), interferonopathies, interstitial lung disease (ILD), progressive fibrosing interstitial lung disease (PF-ILD), and idiopathic pulmonary fibrosis (IPF).

### Claim 22 (depends on 19)

The method according to claim 19, wherein the disease is selected from the group consisting of age-related macular degeneration (AMD), retinopathy, glaucoma, diabetes, obesity, aging, muscle disorders, sepsis, osteoarthritis, heart failure, COVID-19/SARS-CoV-2 infection, renal inflammation, renal fibrosis, dysmetabolism, vascular diseases, cardiovascular diseases and cancer.

### Claim 23 (depends on 1)

A pharmaceutical composition comprising the compound of formula I according to claim 1 and optionally one or more pharmaceutically acceptable carriers and/or excipients.

### Claim 24 (depends on 23)

The pharmaceutical composition according to claim 23 in combination with one or more active agents selected from the group consisting of anti-inflammatory agents, anti-fibrotic agents, anti-allergic agents/anti-histamines, bronchodilators, beta 2 agonists/betamimetics, adrenergic agonists, anticholinergic agents, methotrexate, mycophenolate mofetil, leukotriene modulators, JAK inhibitors, anti-interleukin antibodies, non-specific immunotherapeutics, interferons or other cytokines/chemokines, cytokine/chemokine receptor modulators, toll-like receptor agonists, immune checkpoint regulators, an anti-TNF antibody, Adalimumab, an anti-BAFF antibody, Belimumab and Etanercept,
and optionally one or more pharmaceutically acceptable carriers and/or excipients.

### Claim 25 (depends on 23)

The pharmaceutical composition according to claim 23 in combination with one or more anti-fibrotic agents selected from the group consisting of Pirfenidon and Nintedanib, and optionally one or more pharmaceutically acceptable carriers and/or excipients.

### Claim 26 (depends on 23)

The pharmaceutical composition according to claim 23 in combination with one or more anti-inflammatory agents selected from the group consisting of NSAIDs and corticosteroids, and optionally one or more pharmaceutically acceptable carriers and/or excipients.

### Claim 27 (depends on 23)

The pharmaceutical composition according to claim 23 in combination with one or more active agents selected from the group consisting of bronchodilators, beta 2 agonists/betamimetics, adrenergic agonists and anticholinergic agents, and optionally one or more pharmaceutically acceptable carriers and/or excipients.

### Claim 28 (depends on 23)

The pharmaceutical composition according to claim 23 and one or more anti-interleukin antibodies selected from the group consisting of anti-IL-23 antibodies, Risankizumab, anti-IL-17 antibodies, anti-IL-1 antibodies, anti-IL-4 antibodies, 13 antibodies, anti-IL-5 antibodies, anti-IL-6 antibodies, Tocilizumab, anti-IL-12 antibodies and anti-IL-15 antibodies.
